Quarterly ResultAug 6, 2026, 04:28 PM
Organogenesis Q2 Revenue Plunges 56.7% to $43.76M; Net Loss Widens
AI Summary
Organogenesis Holdings Inc. reported a significant decline in its second-quarter 2026 financial results, with total revenue falling 56.7% to $43.76 million and net loss widening substantially to $96.27 million from $9.39 million in the prior year. The company also implemented restructuring plans in the first and second quarters of 2026, reducing its workforce by a total of 226 employees and incurring charges of $13.88 million. Additionally, the company completed the sale of an asset held for sale in July 2026 for $3.75 million.
Key Highlights
- Q2 2026 total revenue decreased 56.7% to $43.76 million from $101.01 million in Q2 2025.
- Q2 2026 net loss widened to $96.27 million, compared to a net loss of $9.39 million in Q2 2025.
- Basic and diluted net loss per share for Q2 2026 was $(0.77), up from $(0.10) in Q2 2025.
- Year-to-date 2026 net product revenue was $79.06 million, down from $187.47 million in YTD 2025.
- Restructuring plans in Q1 and Q2 2026 reduced headcount by 226 employees with $13.88 million in charges.
- Cash and cash equivalents decreased to $46.10 million at June 30, 2026, from $93.68 million at Dec 31, 2025.
- The Revolving Facility under the 2021 Credit Agreement expired on August 6, 2026, with no outstanding borrowings.
Price Impact
More from ORGO